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Protease nexin I in the murine kidney: Glomerular localization and
up-regulation in glomerulopathies. Protease nexin I (PN-1), a potent
serpin-class antiprotease, is thought to be synthesized in the murine
kidney. However, neither the cellular localization of PN-1 synthesis nor its
role has as yet been defined. To address these questions, we determined by
in situ hybridizations RNase protection assay and immunoblotting, the
sites of PN-1 mRNA accumulation in normal mouse kidneys and the
modulation of PN-1 expression in several pathological conditions. In
normal kidneys, PN-1 mRNA was detected primarily in glomeruli, most
likely in mesangial cells. The glomerufar expression of PN-1 was substan-
tially enhanced not only in lupus-like gtomerulonephritis (induced by IgG3
monoclonal rheumatoid factors or occurring spontaneously in lupus-prone
mice), but also in mild glomerular lesions associated with intracapillary
thrombi induced by IgG3 anti-trinitrophenyl monoclonal antibodies. In
contrast, no modulation of PN-i mRNA levels was observed during the
course of lipopolysaccharide-induced acute tubular necrosis. A constitu-
tive PN-1 gene expression and its up-regulation during glomerular injury
suggest a possible role for PN-l in glomerular biology. In view of its high
inhibitory activity towards thrombin, mesangial PN-1 may be involved in
the control of glomerular coagulation following initial glomerular injuries.
Protease nexin I (PN-I), also known as glia-derived nexin, is a
potent inhibitor of certain tlyptic serine proteases, including
thrombin, plasminogen activators and plasmin [1—4]. PN-1 is
synthesized mainly in the genital tract and in the brain, particu-
larly in the olfactory bulb; other tissues including the kidney also
express PN-1 [5—7]. The enhanced expression of PN-1 has been
observed in lesions of the central and peripheral nervous systems
[8, 9], or following the stimulation of different types of cells by
inflammatory cytokines such as interleukin 1 (IL-i), tumor necro-
sis factor a (TNF-a) and transforming growth factor f3 (TGF-13)
(10, 11]. Although the biological role of PN-1 has not yet been
defined, it may play a regulatory function as an inhibitor of
thrombin in limiting coagulation in physiological and pathological
conditions.
It has been suggested that a dysregulation in glomerular
coagulation may be involved in the progression of glomerular
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lesions, most notably towards glomeruloscierosis, which is consid-
ered to be the final pathway leading to renal insufficiency in a
number of glomerulonephritis including lupus nephritis [12—15].
Fibrin deposits could promote glomerular injuries by occluding
capillaries and by promoting inflammatory cell migration and
glomerular cell proliferation [16]. This is consistent with the
finding that anticoagulant treatment can prevent the development
of glomerulosclerosis in an experimental model of glomerulone-
phritis [17]. To gain further insight into the functional activity of
PN-i in kidneys, we determined the sites of PN-1 mRNA accu-
mulation in normal mouse kidneys, and modulation of PN-1
expression during the course of several pathological conditions.
They include two different types of glomerular lesions (lupus-like
glomerulonephritis and glomerular lesions associated with intra-
capillary thrombi) induced by murine IgG3 monoclorial antibod-
ies (mAb) [18—20], chronic glomerulonephritis occurring sponta-
neously in lupus-prone (NZB x NZW)F1, MRL-lprllpr and BXSB
mice [21], and acute tubular necrosis induced by bacterial lipo-
polysaccharides (LPS) [22].
Methods
Mice
C57BL16 and BALB/e mice were obtained from Bomholtgard
Ltd. (Ry, Denmark). (NZB x NZW)F1, BXSB, MRL-lprllpr and
MRL-+I+ mice were purchased from Harlan Olac Ltd. (Oxon,
UK). (MRL-+/+ x BALB/c)F1 hybrid (MRLxBALB) mice were
bred in our own animal facilities.
Mesangial cells
RNA from murine mesangial cells, isolated and cultured ac-
cording to the method of MacKay et a! [231, were kindly provided
by Dr. E. Muso, Department of Internal Medicine, Faculty of
Medicine, Kyoto University, Kyoto, Japan.
Monoclonal antibodies
Murine hybridoma cells secreting IgG3 mAb with anti-IgG2a
rheumatoid factor (RF) activity (6-19, 1-10B4 and AM16) were
obtained from unmanipulated MRL-lprllpr mice [19]. IgG3 anti-
trinitrophenyl (TNP) mAb (CB1 and 9A6) were established from
TNP-immunized C57BL/6 and BALB/c mice, respectively [24].
Hybridoma cells producing the 6-19 1gM or IgGi class switch
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Fig. 2. . RIVase protection analysis of PN-l and GAPDH mRNA in kidneys from mice injected with hybridoma cells secreting 6-19 IgG3 RF mAb.
MRLxBALB mice were sacrificed at days 0, 3, 5 and 7 after the injection of hybridoma cells. Five micrograms of total kidney RNA from three mice
at each time point were individually analyzed for the presence of PN-1 and GAPDH mRNA using corresponding eRNA probes. B. Quantitative analysis
of renal PN-1 versus GAPDH mRNA abundance in kidneys from mice injected with hybridoma cells secreting 6-19 Ig class switch variants. Animals
were sacrificed 7 to 10 days after the injection of hybridoma cells secreting 6-19 IgG3 (y3), IgGI (yl) or 1gM (tt) switch variant. PN-l and GAPDH
mRNA were analyzed in individual mice by the RNase protection assay using PN-1 and GAPDH cRNA probes simultaneously. The intensity of each
signal was quantified by phosphor imager analysis, and results are expressed as a ratio of the radioactivity associated with the PN-1 signal relative to
that of the GAPDH signal in individual animals.
variant lacking cryoglobulin activity were generated as described
previously [25, 26j. iO hybridoma cells were injected i.p. into
three-month-old pristane-treated MRLxBALB mice. Mice were
sacrificed three, five and seven days after the injection of 6-19
hybridoma cells, and between 7 and 10 days for other hybridoma
cells.
Depletion of platelets
Mice injected with hybridoma cells secreting 6-19 mAb on day
0 were treated with rabbit anti-mouse platelet antibodies on days
1, 3 and 4 (2 mg/mouse for each injection). As a control, mice
were treated with polyclonal rabbit IgG.
LI'S treatment
Mice were injected i.p. with 100 jxg LPS from Escherichia coli
(Sigma Chemical Co., St. Louis, MO, USA). Animals were
sacrificed 3, 8 and 48 hours post-injection.
Probe preparations
PN-1 antisense RNA probe was transcribed in vitro with T7
RNA polymerase using pGEM 3Z-PN-1 containing the 1.0-kb
PstI fragment of the murine PN-1 eDNA, linearized with XbaI for
in situ hybridization and with Ace! for RNase protection assays
[5]. PN-1 sense RNA probe was transcribed with SP6 RNA
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Fig. 1. A. Renal localization of PN-1 mRNA
accumulation in normal mice. Cryostat kidney
sections from six-month-old C57BL/6 mice were
hybridized with 32P-labeled PN-1 antisense and
sense RNA probes. Note that PN-1 mRNA is
specifically detected in the cortex with a
speckled pattern corresponding to a glomerular
localization, in the medulla, particularly at the
corticomedullary junction, and in the papilla.
Fig. 3. A. Glomerular up-regulation of PN-1
mRNA abundance in mice injected with
hybridoma cells secreting 6-19 JgG3 mAb.
Cryostat kidney sections from 6-19 hybridoma-
injected mice at day 0 (DO), 3 (D3), 5 (D5) and
7 (D7) were hybridized with 32P-labeled PN-l
cRNA antisense probe. Note a marked and
selective glomerular accumulation of PN-1
mRNA seven days after the 6-19 hybridoma
injection (D7).
polymerase using the murine PN-1 cDNA linearized with EcoRI
[5j. The murine plasminogen activator inhibitor type I (PAl-I)
antisense RNA probe was transcribed with T3 RNA polymerase
using pBSKS-PAI-1 containing the 0.3-kb SmaI fragment of the
3' coding region of the murine PAT-i eDNA (gift from Dr.
Pierre-Alain Menoud, Department of Medicine, University of
Geneva) [271, linearized with XbaI. The glyceraldehyde-3-phos-
phate-dehydrogenase (GAPDH) antisense RNA probe was pre-
pared as described previously [28].
RNase protection assay
RNase protection assays were performed as described [29].
Briefly, five g of total RNA extracted from whole kidneys and
from cultured mesangial cells were hybridized for 16 hours with
a[32P]UTP-labeled antisense PN-1, PAl-I and GAPDH ribo-
probes at 42°C. Yeast tRNA was used as control. Unhybridized
RNA was digested with RNase A (Sigma) for one hour at 25°C.
The RNase was then digested with proteinase K (Sigma) for 20
minutes at 35°C. After phenol-chloroform extraction and sodium
acetate precipitation, the protected RNA was denatured at 90°C
and electrophoresed on a urea-6% polyacrylamide gel. The dried
gels were exposed to autoradiographic films (Kodak X-Omat film,
Eastman Kodak, Rochester, NY, USA) and subjected to phos-
phor imager analysis for quantification (Image Quant Software
FAST SCAN; Molecular Dynamics Ltd, Kemsing, UK) [301.
In situ hybridization
Kidneys were frozen in methyl butane and kept at —70°C until
analyzed. Five-micrometer cryostat tissue sections were fixed in
4% glutaraldehyde in PBS for one minute. Prehybridizations,
hybridizations and posthybridization washes were carried out as
described [31]. Two >< i0' cpm of 32P-labeled RNA or 0.4 X 106
cpm of 3H-labeled RNA were applied to each cryostat kidney
tissue section in 30 d of hybridization mixture. After graded
ethanol dehydration, sections hybridized to 32P-labeled RNA
were directly exposed to X-ray films (SB5; Eastman Kodak Co.)
between intensifying screens, and the films developed after 14
days' exposure at room temperature. Sections hybridized to
3H-labeled RNA were immersed in NTB-2 emulsion (Eastman
Kodak), diluted 1:1 in deionized water. After 16 weeks of
exposure, they were developed in Kodak D-19 developer, fixed in
30% sodium thiosulfate, and counterstained with methylene blue.
SDS-PAGE and immunoblotting
Mouse kidneys were homogenized in 20 mrvi Tris pH 8.0 and
150 mivi NaC1. One hundred microliters of each sample were
adsorbed with 200 .d of Staphylococcus aureus protein A (Pan-
sorbin, Calbiochem-Novabiochem, La Jolla, CA, USA) in order to
eliminate IgG present in kidney homogenates. Protein concentra-
tions were determined by the method of Lowry [321, using bovine
a 0'
I
¾
4&
S
a
4
4
Moll et al: Renal expression of protease nexin I in mice 1939
Fig. 1. Continued. B. Cellular sites of
glomerular PN-1 mRNA accumulation in
normal mice. Cryostat kidney sections from six-
month-old C57BL/6 mice were hybridized with
3H-labeled PN-1 cRNA antisense probe. Upper
left panel is bright-field micrograph (X40) and
upper right panel is the corresponding dark-
field micrograph. Lower panel is bright-field
micrograph (X100), showing the glomerular,
most likely mesangial cell localization of PN-1
mRNA accumulation.
Fig. 3. Continued. B. Mesangial up-regulation
of PN-1 mRNA abundance in mice injected
with hybridoma cells secreting 6-19 IgG3 mAb.
Cryostat kidney sections from 6-19 hybridoma-
injected mice at day 7 were hybridized with 3H-
labeled PN-1 cRNA antisense probe. Upper left
panel is bright-field micrograph (x40) and
upper right panel is the corresponding dark-
field micrograph. Lower panel is bright-field
micrograph (X 100). Note an increased
accumulation of PN-1 mRNA in glomeruli,
most likely in mesangial cells.
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Fig. 4. PN-1 mRNA accumulation and localization in kidneys from three different lupus-prone (NZB x NZW)F1, MRL-lpr/lpr and BXSB mice. Total RNA
of kidneys from lupus-prone and non-autoimmune (C57BL/6) mice of different ages were analyzed by the RNase protection assay using PN-1 and
GAPDH cRNA probes simultaneously; two different RNase-protected bands (410 bp for PN-1 and 260 bp for GAPDH) are revealed. RNA extracted
from yeast (*) was used as a negative control in each assay. Cryostat kidney sections from lupus-prone mice having severe glomerulonephritis were
analyzed by in situ hybridization with 32P-labeled PN-1 cRNA antisense probe. Note a marked up-regulation of PN-1 accumulation with a speckled
glomerular localization in diseased kidneys from three different lupus mice, as compared with six-month-old non-autoimmune C57BL/6 mice.
serum albumin (BSA) as a standard. SDS-PAGE and immuno- ferred onto nitrocellulose membrane (Schleicher & Schuell, Rie-
blotting were performed as described [7j. Briefly, 100 xg protein hen, Switzerland). Membranes were blocked for non-specific
samples were heated five minutes at 100°C in 20% 2-Mercapto- antibody binding in 1.5% skimmed milk in Ca2 and Mg2-free
ethanol, electrophoresed on a 8% polyacrylamide gel and trans- PBS for one hour at room temperature, incubated overnight at
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Histological grades Histological grades Histological grades
Fig. 5. Quantitative analysis of renal EN-i versus GAPDH mRNA abundance in relation to the intensity of glomendar lesions in three diffrrcnt lupus-prone
mice: (A) (NZB x NZW)F1, (B) MRL-lpr/lpr and (C) BXSB. Total RNA of kidneys from lupus-prone mice of different ages were analyzed by the RNase
protection assay using PN-l and GAPDH cRNA probes simultaneously. The ratio of the radioactivity associated with the PN-l signal relative to that
of the GAPDH signal in individual animals was computed from the intensity of each signal determined by phosphor imager analysis. PN-1/GAPDH
mRNA ratios were correlated with the severity of glomcrular lesions, expressed as histological grades based on the intensity and extent of
histopathological changes, in individual animals.
6—19 1 — 10B4 AM16 CB1 9A6 Control
Fig. 6. Quantitative analysis of renal Pb/-i and PAl-I versus GAPDH
mRNA abundance in mice injected with different hybridoma cells secreting
IgG3 mAb. Mice were injected with cells secreting the following lgG3
mAb: 6-19 RF, 1-10B4 RF, AM16 RF, CBI anti-TNP and 9A6 anti-TNP.
Total RNA of kidneys were prepared from mice 7 to 10 days after the
injection of hybridoma cells. PN-t, PAl-i and GAPDH mRNA were
analyzed in individual mice by the RNase protection assay using PN-1,
PAl-i and GAPDH eRNA probes. The intensity of each signal was
quantified by phosphor imager analysis, and results are expressed as a
ratio of the radioactivity associated with the PN-1 (•) orPAl-i (0) signal
relative to that of the GAPDH signal in individual animals.
4°C with a mouse anti-rat PN-1 mAb (4B3) [9] or a control
isotype-matched mAb (CB1). Then, they were incubated for three
hours at room temperature with an alkaline phosphatase-conju-
gated rabbit anti-mouse IgG (Dako, Copenhagen, Denmark), and
immunoreactivity was revealed with 4-nitro blue tetrazolium
chloride and 5-bromo-4-chloro-3-indolyl-phosphate (Boehringer,
Mannheim, Germany).
In situ zymography
In situ zymographies were performed on unfixed cryostat kidney
sections to determine tissue plasminogen activator (tPA)-cata-
lyzed enzymatic activity, using human plasminogen as a substrate
in presence of amiloride, which selectively inhibits uPA-catalytic
activity, as described previously [25].
Histological studies
Samples of kidney tissues were fixed in 10% formalin, and
sections were stained with hematoxylin and eosin, periodic acid-
Schiff (PAS), and phosphotungstic acid reagent to evidence fibrin
deposition. Glomerular lesions in lupus-prone mice were scored
on a 0 to 4+ scale based on the intensity and extent of histopatho-
logical changes, as described previously [25], according to Pirani
and Salinas-Madrigal [33]. Grades 3 and 4 glomerulonephritis are
considered significant contributors to clinical disease and/or
death.
Results
Glomerular localization of PN-1 mRNA in normal mouse kidneys
PN-1 mRNA was detectable by RNase protection assay on totai
kidney RNA from unmanipulated C57BL/6 mice, as described
previously (Fig. 4)[S, 7]. To localize the sites of PN-1 mRNA
accumulation, frozen kidney sections from C57BL/6 mice were
hybridized with either 32P- or 3H-labeled PM-i cRNA probes.
PN-1 mRNA was detected primarily in the cortex with speckled
signals, suggesting a glomerular localization; no hybridization
signals were observed with control sense RNA probe (Fig. IA).
Cellular sites of glomerular PN-i mRNA accumulation, as dis-
closed by kidney sections hybridized to 3H-labeled PN-1 cRNA,
were identified most likely as mesangial cells (Fig. I B). PN-1
mRNA was indeed detectable by RNase protection assay on RNA
extracted from murine cultured mesangial cells (data not shown).
Although less well defined signals with 32P-labeled PN-i cRNA
were occasionally seen at the cortico-medullary junction and in
the papilla, no specific cellular signals, when hybridized to 3H-
labeled probe, were detected in these extraglomerular sites (data
not shown).
Enhanced glomerular accumulation of PN- I mRNA in acute
lupus-like glomerulonephritis induced by IgG3 RF mAb
Intraperitoneal implantation of hybridoma cells secreting 6-19
IgG3 monoclonal RF with cryoglobulin activity induces acute
glomerulonephritis characterized by subendothelial deposits re-
sembling "wire-loop" lesions seen in human lupus nephritis and
fibrin deposits admixed in intraluminal thrombi obstructing the
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Fig. 7. Immunoblot analysis of renal PN-I protein abundance in mice injected with diJftrent hybridoma cells secreting !gG3 mAb and in lupus-prone BXSB
mice. Kidney extracts (100 jsg proteins) were loaded after adsorbtion with Pansorbin, and PN-1 immunoreactivity was revealed using the 4B3 anti-PN-1
mAb or an isotype-matched control mAb, followed by alkaline phosphatase-labeled rabbit anti-mouse IgG conjugate. A. Immunoblot analysis of kidney
extracts from 6-19 RF hybridoma-injected mice at days 0 (DO), 3 (D3), 5 (D5) and 7 (D7) or from 9A6 anti-TNP hybridoma-injected mice at day 7 (9A6).
Note that the PN-1 levels progressively increase with the development of 6-19 RF-induced glomerular lesions, and that the increase of PN-1 is more
pronounced in mice receiving 9A6 mAb. B. Immunoblot analysis of kidneys from mice injected with hybridoma cells secreting 9A6 or CB1 anti-TNP
IgG3 mAb, of kidneys from six-month-old lupus-prone BXSB mice, and of seminal vesicle (VS), using anti-PN-1 (a-PN-1) or control mAb. Note that
extracts from kidneys exhibit a 45 kDa band (arrowheads), specifically recognized by the 4B3 anti-PN-1 mAb, the position of which corresponds to that
of PN-1 protein detected in seminal vesicle 151.
capillary lumen [18j. We examined whether renal PN-1 mRNA
abundance was modulated during the course of an acute lupus-
like glomerulonephritis induced by murine IgG3 monoclonal
cryoglobulins. PN-1 mRNA levels, as measured by RNase protec-
tion assays on total kidney RNA, progressively increased with the
development of glomerular lesions (Fig. 2A); quantitative analy-
sis, normalized to GAPDH mRNA levels, revealed a moderate (2-
to 3-fold) increase in PN-1 mRNA abundance five and seven days
after the 6-19 hybridoma injection, as compared with control mice
(Fig. 2B). Notably, other nephritogenic IgG3 monoclonal RF
cryoglobulins, 1-10B4 and AM16, similarly increased renal PN-1
mRNA levels (Fig. 6). A nonspecific effect of hybridoma cell
injections on renal PN-1 mRNA accumulation was ruled out,
since implantation of hybridoma cells producing the 6-19 IgGi or
1gM class switch variant, which generates neither cryoglobulins
nor glomerular lesions, failed to up-regulate PN-1 mRNA expres-
sion in kidneys (Fig. 2B).
To define the tissue localization of PN-1 mRNA up-regulation,
kidney sections obtained from mice injected with 6-19 hybridoma
cells were hybridized to PN-1 cRNA probes. The cortex in 6-19
hybridoma-injected mice displayed a marked reinforcement of
speckled signals at day 7 without any changes in the medullary and
papillary PN-1 mRNA abundance (Fig. 3A). This selective gb-
merular, most likely mesangial, up-regulation of PN-i mRNA
expression was confirmed by analysis of kidney sections hybridized
to a 3H-labeled probe (Fig. 3B). The possible involvement of
inflammatory cells in glomerular PN-l mRNA up-regulation was
unlikely, because their glomerular infiltration was most prominent
at day 5, but almost undetectable at day 7.
Since platelets are known to express PN-1 [34], we determined
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glomerular PN-1 mRNA abundance in mice depleted of platelets
following the injection of 6-19 hybridoma cells. The anti-platelet
antibody treatment resulted in an almost complete depletion of
platelets at the time of the sacrifice (day 0, 1.66 0.11 X
1061mm3; day 5, 0.01 0.01 X 1061mm3). No modulation of PN-1
mRNA levels, as measured by RNase protection assays on total
kidney RNA, was observed in mice depleted of platelets (data not
shown). Notably, these mice developed typical "wire-loop" gb-
merular lesions at intensities comparable to those seen in control
mice.
Enhanced glomerular accumulation of PN-1 mRNA in chronic
lupus nephritis occurring spontaneously in lupus-prone mice
Using three different lupus-prone mice [(NZB x NZW)F1,
MRL-lprllpr and BXSBI, the renal abundance of PN-1 mRNA was
assessed in relation to the development of their glomerular
lesions. For this purpose, total RNA was extracted from kidneys
of lupus-prone mice of various ages, and PN-1 and GAPDH
mRNA abundance were simultaneously analyzed by RNase pro-
tection assay, in which two different sizes of RNase-protected
bands (410 bp for PN-1 and 260 bp for GAPDH) were revealed.
All three lupus-prone mice exhibited an increased abundance of
PN-1 mRNA concomitantly with the development of severe
glomerular lesions, that is, at 9 months for (NZB x NZW)F1
females, 4 months for MRL-Iprllpr females, and 5 to 8 months for
BXSB males (Fig. 4). This was in marked contrast to the absence
of any changes in the abundance of PN-1 mRNA in female BXSB
mice, which fail to develop lupus-like nephritis during the first
year of their life [21], and in non-autoimmune C57BL/6 mice.
Quantitative analysis, normalized to GAPDH mRNA levels,
revealed a correlation between PN-1 mRNA levels and histolog-
ical grades in individual lupus-prone mice (Fig. 5).
In situ hybridization studies of PN-1 mRNA accumulation sites
in the three lupus-prone mice yielded results essentially identical
to those obtained from mice injected with 6-19 mAb. Markedly
enhanced accumulation of PN-1 mRNA was confined to the
cortex, with speckled glomerular localization (Fig. 4). Kidney
sections hybridized to 3H-labeled PN-1 cRNA confirmed a mes-
angial localization (data not shown).
Enhanced glomerular accumulation of PN-J mRNA in glomerular
lesions associated with intracapillaiy thrombi
To further define the role of PN-1 during glomerular injury, we
examined the PN-1 gene expression in a different type of glomer-
ular lesion characterized by intracapillary thrombi and mesangial
deposits, but not "wire-loop" lesions; these lesions were induced
by the injection of IgG3 anti-TNP mAb [201. The implantation of
IgG3 anti-TNP (CB1 and 9A6) hybridoma cells resulted in a
significant increase in renal PN-1 mRNA at levels comparable or
even higher than those induced by IgG3 RF mAb (Fig. 6). It
should be emphasized that 9A6 mAb, which lack a cryoglobulin
activity, but are still capable of generating microaggregates as a
result of non-specific y3 Fc-Fc interaction [241, were able to
induce only mild glomerular lesions as compared with CB1 mAb
[20]; however, PN-i mRNA levels in mice receiving 9A6 mAb
were comparable to those of CB1 mAb-injected mice.
Enhanced expression of PN-1 protein in the different types of
glomerular lesions
To determine whether PN-1 mRNA modulations were associ-
ated with concomitant quantitative changes in PN-1 protein
accumulation, we analyzed kidney extracts by immunoblotting.
The intensity of a 45 kD band, specifically recognized by the 4B3
anti-PN-1 mAb, progressively increased during the course of
acute lupus-like glomerulonephritis induced by 6-19 IgG3 mono-
clonal cryogbobulins (Fig. 7A). This increase was even more
pronounced in mice developing gbomerular intracapillary throm-
botic lesions induced by 9A6 and CB1 lgG3 anti-TNP mAb (Fig.
7). We also observed a substantial increase in the renal PN-1
levels of lupus-prone mice, BXSB (Fig. 7B), (NZB x NZW)F1 and
MRL-lprllpr (data not shown).
Differential expression of PN-1 and PAl-i mRNA in different
glomerular pathologies
Since it has been shown that a dysregulation of the gbomerular
PAJPAI-1 balance, as a result of a marked induction of PAl-i
gene expression, may play a role in the development and progres-
sion of lupus-like glomerulonephritis [25, 35], renal PN-1 mRNA
abundance was compared with that of PAl-i mRNA in two
different types of gbomerular lesions induced by IgG3 mAb. In
mice developing lupus-like glomerulonephritis induced by IgG3
RF cryoglobulins (6-19, 1-10B4 and AM16), both PN-1 and PAl-i
mRNA abundance was up-regulated in parallel, although the
enhancement of PAl-i mRNA levels was far more striking (Fig.
6). In contrast, minimal or little induction of renal PAl-i mRNA
was observed in mice developing only gbomerular intracapillary
thrombotic lesions induced by IgG3 anti-TNP mAb (CB1 and
9A6), while their renal abundance of PN-i mRNA were almost
comparable to those seen in mice developing severe lupus-like
glomerulonephritis. It should be mentioned that zymographic
analyses showed no diminishment in tPA-catalyzed enzymatic
activity over gbomerular lesions associated with intracapillary
thrombi (data not shown), which contrasted with a significant
decrease in gbomerular tPA-catalyzed activity in mice developing
lupus-like glomerubonephritis [251.
Absence of PN-i mRNA modulation during the course of acute
tubular necrosis induced by LPS
LPS has been shown to induce marked alterations in tubular
and glomerular proteolytic balance by modulating PA and PAl-i
expression, concomitant with the development of acute tubular
necrosis in mice [22]. The renal abundance of PN-1 mRNA
following the injection of LPS in C57BL/6 mice was determined by
RNase protection assay. Comparative measurements of PN-1 and
GAPDH mRNA levels did not show any significant changes in the
renal PN-1 mRNA abundance (data not shown).
Discussion
In the present study, we have demonstrated that glomeruli,
most probably mesangial cells, are the major site of PN-1 mRNA
accumulation in normal and diseased kidneys, and that the
gbomerular PN-1 expression is augmented not only in mice
developing lupus-like glomerulonephritis, but also in mice having
mild gbomerular lesions characterized by intracapillary thrombi.
An up-regulation of PN-i expression in various glomerular pa-
thologies, in particular in those associated with intracapillary
thrombi without evolution towards sclerotic lesions, suggests an
involvement of PN-1 in the control of glomerular coagulation
following initial gbomerular injuries.
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In situ hybridization experiments have disclosed that glomeruli
are the principal site of PN-l mRNA accumulation under physi-
ological conditions. Even though resolution of the in situ hybrid-
izations on cryostat tissue sections is relatively limited, our results
suggest that mesangial cells are the major site of PN-1 gene
expression. This notion is supported by the detection of PN-1
mRNA in cultured mesangial cells and by the increased accumu-
lation of PN-I mRNA transcripts in the mesangium of diseased
kidneys, although the possible involvement of inflammatory cells
in the increased PN-l mRNA accumulation cannot be excluded,
particularly in glomerular lesions occurring in lupus-prone mice.
In addition to glomcruli, there were lower, but significant, PN-1
mRNA levels in the medulla, particularly at the corticomedullary
junction, and in the papilla. The absent detection of specific
cellular signals in these extraglomerular sites, when hybridized to
3H-labeled PN-1 cRNA, may be due to limited levels of their PN-1
mRNA abundance, as compared with the glomerular expression.
It is significant that the glomerular, most likely mesangial, PN-1
gene expression is up-regulated in two different types of glomer-
ular lesions: lupus-like glomerulonephritis and glomerulopathies
associated with intracapillary thrombi and mesangial deposits.
The enhanced PN-1 gene expression in diseased glomeruli may
result from increased local expression of thrombin, which can
induce PN-1 biosynthesis [2], and/or of cytokines released follow-
ing glomerular injuries. In fact, we and others have demonstrated
an up-regulation of glomerular TGF-pl, IL-I and TNF-a mRNA,
all of which are known to increase PN-1 expression in vitro [10,
II], in IgG3 cryoglobulin-induced and spontaneous lupus-like
glomerulonephritis [25, 35, 36].
The role of PN-1 in kidneys remains to be defined. Since PN-1
is a potent inhibitor of thrombin and PA [1, 2, 37], glomerular
PN-l may be involved in the control of intraglomerular coagula-
tion in physiological and pathological conditions. In this respect, it
should be mentioned that we and others have recently demon-
strated remarkable increases in glomerular expression of another
serine protease inhibitor, PAl-I, leading to a significant decrease
in glomerular tPA-catalyzed enzymatic activity during the course
of acute and chronic lupus-like glomerulonephritis [25, 351.
However, we did not observe any changes in glomerular tPA-
catalyzed activity in mice developing glomerular intracapillary
thrombotic lesions induced by IgG3 anti-TNP mAb (9A6), in
which PN-1 expression is highly significantly increased without any
modulation in tPA and PAL-I mRNA levels [251. This result
suggests that PN-1 plays at best a minor role as an inhibitor of PA
in these types of glomerular lesions. Thus, it can be speculated
that the up-regulation of PN-l gene expression during glomerular
injury might be a host response to down-regulate thrombin
activity, thereby protecting glomeruli against excessive generation
and deposition of fihrin. In contrast, an excessive induction of
PAT-l synthesis, probably mediated by an increased glomerular
production of TGF-/31 [38], might favor progression towards
glomerulosclerosis by reducing glomerular fibrinolysis [39—41].
This idea is consistent with the findings that glomerular PN-1 gene
expression, as compared with PAL-I gene expression, is more
dramatically involved during the development of relatively mild
glomerular lesions associated with intracapillary thrombi without
evolution towards glomerulosclerosis, while the increase in PAT-i
gene expression is far more striking in mice developing lupus-like
glomerulonephritis with an evolution towards sclerotic lesions.
Thus, an imbalance between PN-i and thrombin, in addition to a
perturbation of the glomerular PA/PAl-I balance, could be one of
the important factors in the process of glomerular fibrin deposi-
tion, and hence in the eventual progression to glomerulosclerosis.
In addition, it has been shown that the PN-1-mediated inhibition
of thrombin is specifically enhanced by heparan sulfate and
chondroitin sulfate, the major components of the glomerular
extracellular matrix [371. Reduced synthesis of these glomerular
proteoglycans occurring during the course of certain forms of
glomerulonephritis [42, 31 might result in a decrease of the
anti-thrombin activity of PN-l, thereby additionally contributing
to the progression of glomerular lesions.
The present observation suggests that PN-l, most likely ex-
pressed by mesangial cells, may help maintain glomerular function
by participating in the control of intraglomerular coagulation.
This possible function of PN-I may be important during the
course of glomerulopathies. An attractive hypothesis is that PN-1
plays a protective role during glomerular injury by limiting the
deposition of fibrin and hence retarding the subsequent develop-
ment of glomerulosclerosis. Further elucidation of the role(s) of
glomerular serpins in mice deficient in PN-1 or in PAT-I could
help us understand the pathogenetic process implicated in gb-
merulosclerosis and establish new therapeutic strategies for lupus
nephritis and other glomerular pathologies.
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Appendix
Abbreviations are: PN-l, protease nexin 1; IL-i, interleukin 1; TNF-a,
tumor necrosis factor a; TGF-, transforming growth factor mAb,
monoclonal antibody; LPS, lipopolysaccharide; MRLxBALB, (MRL-+I+
x BALB/c)F1 hybrid; RF, rheumatoid factor; TNP, trinitrophenyl; PAl-I,
plasminogen activator inhibitor type t; GAPDH, glyceraldehyde-3-phos-
phate-dehydrogenase; PAS, periodic acid Schiff.
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